These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34620281)

  • 1. The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression.
    Zheng L; Du J; Ge F; Qian M; Yang B; He Q; Weng Q; Zhu H
    Pharmazie; 2021 Oct; 76(10):511-514. PubMed ID: 34620281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ.
    Zhu H; Yan F; Yuan T; Qian M; Zhou T; Dai X; Cao J; Ying M; Dong X; He Q; Yang B
    Cancer Res; 2020 Jun; 80(11):2204-2216. PubMed ID: 32217697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod exerts
    Du J; Qian M; Yuan T; Zhang B; Chen X; An N; He Q; Yang B; Ye S; Zhu H
    Acta Pharm; 2022 Sep; 72(3):427-436. PubMed ID: 36651547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SEPTIN10-mediated crosstalk between cytoskeletal networks controls mechanotransduction and oncogenic YAP/TAZ signaling.
    Weiler SME; Bissinger M; Rose F; von Bubnoff F; Lutz T; Ori A; Schirmacher P; Breuhahn K
    Cancer Lett; 2024 Mar; 584():216637. PubMed ID: 38242197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SDHA/B reduction promotes hepatocellular carcinoma by facilitating the deNEDDylation of cullin1 and stabilizing YAP/TAZ.
    Yuan T; Zhou T; Qian M; Du J; Liu Y; Wang J; Li Y; Fan G; Yan F; Dai X; Li X; Wu Y; Dong X; He Q; Zhu H; Yang B
    Hepatology; 2023 Jul; 78(1):103-119. PubMed ID: 35713976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.
    Cho K; Ro SW; Lee HW; Moon H; Han S; Kim HR; Ahn SH; Park JY; Kim DY
    Hepatology; 2021 Nov; 74(5):2605-2621. PubMed ID: 34101869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
    Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
    Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
    J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Therapeutically Targetable TAZ-TEAD2 Pathway Drives the Growth of Hepatocellular Carcinoma via ANLN and KIF23.
    Saito Y; Yin D; Kubota N; Wang X; Filliol A; Remotti H; Nair A; Fazlollahi L; Hoshida Y; Tabas I; Wangensteen KJ; Schwabe RF
    Gastroenterology; 2023 Jun; 164(7):1279-1292. PubMed ID: 36894036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous knockdown of YAP and TAZ increases apoptosis of hepatocellular carcinoma cells under hypoxic condition.
    Yan B; Li T; Shen L; Zhou Z; Liu X; Wang X; Sun X
    Biochem Biophys Res Commun; 2019 Jul; 515(2):275-281. PubMed ID: 31146919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nogo-B fosters HCC progression by enhancing Yap/Taz-mediated tumor-associated macrophages M2 polarization.
    Zhao X; Wang X; You Y; Wen D; Feng Z; Zhou Y; Que K; Gong J; Liu Z
    Exp Cell Res; 2020 Jun; 391(1):111979. PubMed ID: 32246992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma.
    Zhao C; Gong J; Bai Y; Yin T; Zhou M; Pan S; Liu Y; Gao Y; Zhang Z; Shi Y; Zhu F; Zhang H; Wang M; Qin R
    Cell Death Differ; 2023 Jan; 30(1):1-15. PubMed ID: 35906484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness.
    Park H; Lee Y; Lee K; Lee H; Yoo JE; Ahn S; Park YN; Kim H
    Pathol Oncol Res; 2021; 27():604600. PubMed ID: 34257565
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation of myocardial glucose metabolism by YAP/TAZ signaling.
    Kashihara T; Sadoshima J
    J Cardiol; 2024 May; 83(5):323-329. PubMed ID: 38266816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of cyclo-oxygenase-2 and yap/taz in hepatocellular carcinoma in untreated and treated hepatitis C virus patients.
    Sweed D; Abd-Elbary A; Sweed E; Mosbeh A; Moaz I; Yassein T; Elmashad S
    Pol J Pathol; 2022; 73(2):88-98. PubMed ID: 35979755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis.
    Gao R; Kalathur RKR; Coto-Llerena M; Ercan C; Buechel D; Shuang S; Piscuoglio S; Dill MT; Camargo FD; Christofori G; Tang F
    EMBO Mol Med; 2021 Dec; 13(12):e14351. PubMed ID: 34664408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.